MindBio Therapeutics Corp. (MBIO.CN)

0.0700 +0.0100 (+16.67%) As of 03:03PM EDT. Market open.

MindBio Therapeutics Corp.

1055 West Georgia Street
Vancouver, BC
Canada

https://www.mindbiotherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Justin Adam Hanka	Co Founder, CEO & Director	N/A	N/A	1974
Mr. John M. Dinan	Chief Financial Officer	N/A	N/A	1958
Dr. Lahiru Russell Ph.D.	Chief Scientist	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Canada, Australia, and New Zealand. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, PTSD, panic disorder, chronic pain, and opiate addictions. Its LSD-microdosing is currently under Phase 2 clinical trials for the treatment of major depressive disorder and microdosing of LSD in late-stage cancer patients. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.

Corporate Governance

MindBio Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.